Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

Rhea-AI Summary

Pyxis Oncology (Nasdaq: PYXS) announced that CEO Lara Sullivan and the management team will present at two upcoming investor conferences.

• H.C. Wainwright Global Investment Conference: May 24, 2022, at 7:00 a.m. ET; format includes pre-recorded presentation and virtual meetings.
• Jefferies Healthcare Conference: June 8, 2022, at 2:00 p.m. ET; format includes live presentation and 1:1 meetings in New York.

Webcasts of the presentations will be available on the company's investor relations site and can be replayed for 90 days.

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, and members of the management team will present at the following upcoming investor conferences:

H.C. Wainwright Global Investment Conference

Date: Tuesday, May 24, 2022

Time: 7:00 a.m. ET

Format: Pre-recorded presentation available on-demand and virtual 1:1 meetings

Jefferies Healthcare Conference

Date: Wednesday, June 8, 2022

Time: 2:00 p.m. ET

Format: Live presentation and 1:1 meetings in New York, NY

Webcasts of these presentations can be accessed on the Investors section of the Pyxis Oncology website at ir.pyxisoncology.com. A replay of the presentations will be available on the Company’s website for up to 90 days following each event.

About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a multi-asset multi-modality company focused on defeating difficult to treat cancers and improve patient lives. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis Oncology visit www.pyxisoncology.com.

Pyxis Oncology Contact:
Courtney Dugan
Vice President, Head of Investor Relations & Corporate Communications
(617) 500-8872
ir@pyxisoncology.com

FAQ

What are the details of Pyxis Oncology's upcoming presentations at investor conferences in 2022?

Pyxis Oncology will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET, and at the Jefferies Healthcare Conference on June 8, 2022, at 2:00 p.m. ET.

Where can I access the webcasts of Pyxis Oncology's presentations?

Webcasts of the presentations can be accessed on the Investors section of the Pyxis Oncology website.

What is the format of the presentations at the H.C. Wainwright Global Investment Conference?

The format includes a pre-recorded presentation available on-demand and virtual 1:1 meetings.

What format will Pyxis Oncology use for the Jefferies Healthcare Conference?

The Jefferies Healthcare Conference will feature a live presentation and 1:1 meetings in New York.

How long will the replay of Pyxis Oncology’s presentations be available?

Replays of the presentations will be available for up to 90 days following each event.